You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

356 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Feb 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Curative
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Feb 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Mar 2021

Pages